United Therapeutics (UTHR) Long-Term Investments (2009 - 2026)

United Therapeutics (UTHR) has 18 years of Long-Term Investments data on file, last reported at $1.3 billion in Q1 2026.

• For the quarter ending Q1 2026, Long-Term Investments fell 22.99% year-over-year to $1.3 billion; the trailing twelve-month figure through Mar 2026 stood at $1.3 billion (down 22.99% YoY), and the FY2025 full-year result was $1.8 billion, up 20.43% from the prior year.
• Long-Term Investments eased to $1.3 billion in Q1 2026, from $1.8 billion in the prior quarter.
• In the past five years, Long-Term Investments ranged from a high of $2.1 billion in Q3 2023 to a low of $1.3 billion in Q3 2024.
• A 5-year average of $1.6 billion and a median of $1.6 billion in 2025 frame the typical range for Long-Term Investments.
• Across the five-year window, Long-Term Investments soared 45.1% in 2023 and sank 37.92% in 2024, its largest moves.
• Tracing UTHR's Long-Term Investments over 5 years: stood at $1.3 billion in 2022, then soared by 45.1% to $1.9 billion in 2023, then slipped by 22.75% to $1.5 billion in 2024, then grew by 20.43% to $1.8 billion in 2025, then dropped by 25.85% to $1.3 billion in 2026.
• Business Quant data shows UTHR's Long-Term Investments at $1.3 billion in Q1 2026, $1.8 billion in Q4 2025, and $1.6 billion in Q3 2025.